Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665061 | 1.00 | ADORA1 (0.40) | ADORA1ALDH1A1HSD17B10LMNACDK5 | |
| SCHEMBL9412465 | 0.87 | JAK3 (0.32) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4777464 | 0.84 | ADORA1 (0.41) | ADORA1ALDH1A1HSD17B10LMNACDK5 | |
| SCHEMBL30590049 | 0.84 | ADORA1 (0.41) | ADORA1ALDH1A1HSD17B10LMNACDK5 | |
| SCHEMBL5197095 | 0.84 | CYP1A2 (0.39) | ADORA1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL15064128 | 0.82 | EGLN1 (0.32) | LMNA | |
| SCHEMBL9412739 | 0.79 | MAPT (0.35) | ALDH1A1LMNASMN1; SMN2FGFR1FGFR4 | |
| SCHEMBL4307867 | 0.79 | DPP4 (0.49) | ADORA1ALDH1A1HSD17B10LMNANOS1 | |
| SCHEMBL21050252 | 0.79 | PRKD3 (0.42) | ADORA1ALDH1A1HSD17B10LMNACDK5 | |
| SCHEMBL9412606 | 0.78 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334745-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2007047793-A2 | CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA1 32/4885ALDH1A1 4183/4885HSD17B10 4544/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | ADORA1 77/4885ALDH1A1 4840/4885HSD17B10 4689/4885 |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA1 32/4885ALDH1A1 4183/4885HSD17B10 4544/4885 |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA1 32/4885ALDH1A1 4183/4885HSD17B10 4544/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA1 32/4885ALDH1A1 4183/4885HSD17B10 4544/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | ADORA1 58/4885ALDH1A1 4812/4885HSD17B10 4646/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA1 33/4885ALDH1A1 4105/4885HSD17B10 4636/4885 |
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | ADORA1 174/4885ALDH1A1 3802/4885HSD17B10 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.